PURPOSE: The aims of this prospective study were to validate single-photon emission computed tomography (SPECT) with p-[(123)I]iodo-L-phenylalanine (IPA) in brain tumours and to evaluate its potential for the characterisation of indeterminate brain lesions. METHODS: In 45 patients with indeterminate brain lesions or suspected progression of glioma, amino acid uptake was studied using IPA-SPECT and compared with the final diagnosis established by biopsy or serial imaging. After image fusion of IPA-SPECT and magnetic resonance imaging, the presence of tumour was visually determined by two independent observers. IPA uptake was quantified as the ratio between maximum uptake in the suspicious lesion and mean uptake in unaffected brain. RESULTS: Primary brain tumours were present in 35 cases (12 low-grade and 23 high-grade gliomas). Non-neoplastic brain lesions were confirmed in seven cases (three dysplasias, three inflammatory lesions, one lesion after effective therapy). Visual analysis showed a high concordance between the two observers (kappa=0.90, p<0.001), with sensitivity and specificity of 86% and 100% for the discrimination of primary brain tumours and non-neoplastic lesions. At 30 min p.i., IPA uptake in primary brain tumours was higher than that in non-neoplastic lesions (1.70+/-0.36 vs 1.14+/-0.18, p<0.05). Brain metastases showed no increased uptake (1.13+/-0.22, n=3). The persistent retention of IPA in low-grade gliomas without disruption of the blood-brain barrier was visualised up to 24 h p.i. Low-grade and high-grade gliomas showed equivalent IPA uptake (1.72+/-0.37 vs 1.67+/-0.36 at 30 min, p=0.745). CONCLUSION: IPA shows long and specific retention in gliomas. IPA is a promising and safe radiopharmaceutical for the visualisation of gliomas and the characterisation of indeterminate brain lesions.
PURPOSE: The aims of this prospective study were to validate single-photon emission computed tomography (SPECT) with p-[(123)I]iodo-L-phenylalanine (IPA) in brain tumours and to evaluate its potential for the characterisation of indeterminate brain lesions. METHODS: In 45 patients with indeterminate brain lesions or suspected progression of glioma, amino acid uptake was studied using IPA-SPECT and compared with the final diagnosis established by biopsy or serial imaging. After image fusion of IPA-SPECT and magnetic resonance imaging, the presence of tumour was visually determined by two independent observers. IPA uptake was quantified as the ratio between maximum uptake in the suspicious lesion and mean uptake in unaffected brain. RESULTS:Primary brain tumours were present in 35 cases (12 low-grade and 23 high-grade gliomas). Non-neoplastic brain lesions were confirmed in seven cases (three dysplasias, three inflammatory lesions, one lesion after effective therapy). Visual analysis showed a high concordance between the two observers (kappa=0.90, p<0.001), with sensitivity and specificity of 86% and 100% for the discrimination of primary brain tumours and non-neoplastic lesions. At 30 min p.i., IPA uptake in primary brain tumours was higher than that in non-neoplastic lesions (1.70+/-0.36 vs 1.14+/-0.18, p<0.05). Brain metastases showed no increased uptake (1.13+/-0.22, n=3). The persistent retention of IPA in low-grade gliomas without disruption of the blood-brain barrier was visualised up to 24 h p.i. Low-grade and high-grade gliomas showed equivalent IPA uptake (1.72+/-0.37 vs 1.67+/-0.36 at 30 min, p=0.745). CONCLUSION:IPA shows long and specific retention in gliomas. IPA is a promising and safe radiopharmaceutical for the visualisation of gliomas and the characterisation of indeterminate brain lesions.
Authors: Samuel Samnick; Jochen B Bader; Dirk Hellwig; Jean Richard Moringlane; Christof Alexander; Bernd F M Romeike; Wolfgang Feiden; Carl-Martin Kirsch Journal: J Clin Oncol Date: 2002-01-15 Impact factor: 44.544
Authors: W A Weber; S Dick; G Reidl; B Dzewas; R Busch; H J Feldmann; M Molls; C B Lumenta; M Schwaiger; A L Grosu Journal: J Nucl Med Date: 2001-08 Impact factor: 10.057
Authors: Samuel Samnick; Bernd F M Romeike; Boris Kubuschok; Dirk Hellwig; Michaela Amon; Wolfgang Feiden; Michael D Menger; Carl-Martin Kirsch Journal: Eur J Nucl Med Mol Imaging Date: 2004-01-14 Impact factor: 9.236
Authors: Tony Lahoutte; John Mertens; Vicky Caveliers; Philippe R Franken; Hendrik Everaert; Axel Bossuyt Journal: J Nucl Med Date: 2003-09 Impact factor: 10.057
Authors: Dirk Hellwig; Ralf Ketter; Bernd F M Romeike; Andrea Schaefer; Georgios Farmakis; Aleksandar Grgic; Jean R Moringlane; Wolf-Ingo Steudel; Carl-Martin Kirsch; Samuel Samnick Journal: Eur J Nucl Med Mol Imaging Date: 2010-07-30 Impact factor: 9.236
Authors: Richard P Baum; Andreas Kluge; Franz Josef Gildehaus; Marcus Bronzel; Karl Schmidt; Christiane Schuchardt; Stephan Senftleben; Samuel Samnick Journal: Nucl Med Mol Imaging Date: 2011-11-16
Authors: Jennifer L Burkemper; Chaofeng Huang; Aixiao Li; Liya Yuan; Keith Rich; Jonathan McConathy; Suzanne E Lapi Journal: J Med Chem Date: 2015-10-20 Impact factor: 7.446
Authors: Dirk Hellwig; Bernd F M Romeike; Ralf Ketter; Jean R Moringlane; Carl-Martin Kirsch; Samuel Samnick Journal: Eur J Nucl Med Mol Imaging Date: 2007-09-11 Impact factor: 9.236